Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
Phase 3 Completed
514 enrolled
BDH-WM01
Phase 4 Completed
35 enrolled
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Phase 2 Completed
151 enrolled 11 charts
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Phase 1/2 Completed
55 enrolled 9 charts
ImbruVeRCHOP
Phase 1/2 Completed
38 enrolled
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Phase 1/2 Completed
18 enrolled
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Phase 3 Completed
202 enrolled
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Completed
95 enrolled 13 charts
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
33 enrolled 14 charts
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Phase 1 Completed
15 enrolled
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
Phase 1/2 Completed
42 enrolled 8 charts
Bortezomib in Treating Patients With Mantle Cell Lymphoma
Phase 2 Completed
30 enrolled
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Phase 2 Completed
29 enrolled
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Phase 2 Completed
23 enrolled 10 charts
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Phase 2 Completed
289 enrolled 34 charts
BATMAN
Phase 2 Completed
19 enrolled
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Phase 2 Completed
53 enrolled 15 charts
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
Phase 1/2 Completed
107 enrolled 14 charts
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Phase 1 Completed
15 enrolled
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
R2W
Phase 2 Completed
60 enrolled
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Phase NA Completed
23 enrolled 8 charts
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Phase 3 Completed
637 enrolled 15 charts
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
59 enrolled
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
Phase 2 Completed
26 enrolled 14 charts
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
241 enrolled 31 charts
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Phase 2 Completed
63 enrolled 10 charts
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Phase 1 Completed
23 enrolled
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Phase 2 Completed
5 enrolled 4 charts
VCR
Phase 2 Completed
24 enrolled 11 charts
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Phase 2 Completed
30 enrolled 10 charts
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
Phase 2 Completed
40 enrolled 11 charts
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase 2 Completed
279 enrolled 28 charts
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 1/2 Completed
79 enrolled 19 charts
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
Phase 2 Completed
60 enrolled
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Completed
53 enrolled 8 charts
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Phase 2 Completed
121 enrolled
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
Phase 2 Completed
60 enrolled
Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma
Phase 2 Completed
48 enrolled
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Phase 1 Completed
31 enrolled
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 3 Completed
487 enrolled 20 charts
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Phase 1/2 Completed
76 enrolled 6 charts
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Phase 2 Completed
25 enrolled 9 charts
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2 Completed
68 enrolled 9 charts
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Phase 2 Completed
35 enrolled 9 charts
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Phase 2 Completed
15 enrolled 3 charts
ATLL
Phase 1/2 Completed
18 enrolled 13 charts
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Completed
148 enrolled 19 charts